Tania Gendron, PhD, speaks to the present challenges for translating biomarker discoveries to clinical practice and offers ...

Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene ...

SineuGene Therapeutics Co., Ltd. ('SineuGene'), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration ...

The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic ...

Preclinical data with the investigational gene therapy INS1202 show improvements in survival and motor performance in ALS.

Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

including amyotrophic lateral sclerosis (ALS). "At Regeneron, we believe that digital biomarkers have the potential to improve the development of novel therapeutics, and collaboration helps make ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Advocates of TBI awareness are pushing for better care while ASX companies drop devices and drugs that are stepping up the ...